Regardless and in contrast to the alleged beneficial effects of slower growth, higher IDO expression was associated with an improved motility of lung cancer cells that enhanced their metastatic formation in the brain, liver, and bone (71), whereas IDO deficiency decreased metastasic burden and improved the survival of subjects with breast carcinoma-derived pulmonary metastases (72, 73). This evidence concerns the gene IDO1 and breast carcinoma.